Quantcast

Latest VIVUS Inc. Stories

2011-08-05 06:30:00

MOUNTAIN VIEW, Calif., Aug. 5, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that additional data from the phase 3 QNEXA studies will be presented today during the American Association of Diabetes Educators (AADE) meeting in Las Vegas, NV. Ronette L. Kolotkin, PhD, a clinical psychologist from Obesity and Quality of Life Consulting, Consulting Professor at Duke University Medical Center, and former Director of the Behavioral Program at Duke University's Diet &...

2011-08-01 15:00:00

MOUNTAIN VIEW, Calif., Aug. 1, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS), a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today reported its financial results for the second quarter and six months ended June 30, 2011. Second Quarter Results For the second quarter ended June 30, 2011, VIVUS reported a net loss of $16.2 million, or $0.20 per share, as compared to a net loss of $22.8 million, or $0.28 per share, for the...

2011-07-20 05:45:00

MOUNTAIN VIEW, Calif., July 20, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that on August 31, 2011, during the late breaking poster session at the 29th International Epilepsy Congress (IEC) in Rome, Italy, Dr. Alison Pack, Associate Professor of Clinical Neurology, Department of Neurology, Columbia University Medical Center, will present the results of a retrospective study of medical claims data on oral clefts (OC) and major congenital malformations (MCMs) associated...

2011-06-30 05:45:00

MOUNTAIN VIEW, Calif., June 30, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that a New Drug Application (NDA) has been submitted to the U.S. Food and Drug Administration (FDA) seeking approval of avanafil, its investigational drug for the treatment of erectile dysfunction (ED). The NDA submission follows the successful completion of an extensive phase 3 program for avanafil, which included over 1,350 patients, where avanafil was shown to be well tolerated and effective...

2011-06-27 05:45:00

MOUNTAIN VIEW, Calif., June 27, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that multiple posters were presented at the American Diabetes Association (ADA) meeting on June 26th and 27th, 2011, in San Diego, CA. The ADA Scientific Sessions is the world's largest and most prestigious diabetes meeting. Top-line results from the CONQUER and SEQUEL studies have been previously reported, but the ADA presentations represent the first time detailed glycemic results have been...

2011-06-22 05:45:00

MOUNTAIN VIEW, Calif., June 22, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that multiple abstracts have been accepted for presentation at the upcoming American Diabetes Association (ADA) meeting to be held June 24th to June 28th, 2011, at the San Diego Convention Center, San Diego, CA. Timothy Garvey, MD, Professor of Medicine and Chair of the Department of Nutrition Sciences at UAB, will present his findings on the impact of QNEXA treatment on metabolic syndrome....

2011-06-17 05:45:00

MOUNTAIN VIEW, Calif., June 17, 2011 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that the positive results from REVIVE-RP (TA-303), a phase 3 clinical trial evaluating the safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction (ED),will be presented this afternoon at the 2011 Cancer Survivorship and Sexual Health Symposium in Washington D.C. The meeting is jointly sponsored by the International Society for Sexual Medicine (ISSM)...


Word of the Day
virgule
  • A punctuation mark (/) used to separate related items of information.
  • A little rod; a twig.
This word comes from the Late Latin 'virgula,' accentual mark, a diminutive of 'virga,' rod.
Related